Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Suitable and tolerable treatments such as immunotherapy agents have changed the field of bladder cancer, says Hoffman-Censits, especially for patients who are ineligible for cisplatin.

Looking ahead, Hoffman-Censits says that recent advances with targeted therapy and immunotherapy will hopefully lead to longer survival and higher rates of bladder conservation.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Sidney Kimmel Cancer Center at Jefferson

Cancer Centers

Partner

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Dr. Hoffman-Censits Discusses the Future Treatment of Bladder Cancer